The Congenital Disorder of Glycosylation drugs in development market research report provides comprehensive information on the therapeutics under development for Congenital Disorder of Glycosylation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Congenital Disorder of Glycosylation. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Congenital Disorder of Glycosylation and features dormant and discontinued products.
GlobalData tracks six drugs in development for Congenital Disorder of Glycosylation by five companies/universities/institutes. The top development phase for Congenital Disorder of Glycosylation is preclinical with two drugs in that stage. The Congenital Disorder of Glycosylation pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Congenital Disorder of Glycosylation pipeline products market are: Glycomine, Orpha Labs and Maggie’s Pearl.
The key targets in the Congenital Disorder of Glycosylation pipeline products market include Aldose Reductase (Aldehyde Reductase or Aldo Keto Reductase Family 1 Member B1 or AKR1B1 or EC 1.1.1.21), and Peptide N4, N-Acetyl Beta Glucosaminyl Asparagine Amidase (N Glycanase 1 or Peptide:N Glycanase or NGLY1 or EC 3.5.1.52).
The key mechanisms of action in the Congenital Disorder of Glycosylation pipeline product include Aldose Reductase (Aldehyde Reductase or Aldo Keto Reductase Family 1 Member B1 or AKR1B1 or EC 1.1.1.21) Inhibitor with two drugs in Phase III. The Congenital Disorder of Glycosylation pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Congenital Disorder of Glycosylation pipeline products market including Small Molecule, and Recombinant Enzyme.
Congenital Disorder of Glycosylation overview
Congenital disorders of glycosylation (CDG) are a group of rare genetic disorders that affect how proteins in cells add sugar building blocks, called glycans. CDGs are due to single gene defects, chromosomal disorders, multifactorial inheritance, environmental teratogens, or micronutrient deficiencies. Symptoms include hypotonia, poor growth, developmental delays, liver disease, abnormal bleeding, and stroke-like episodes. Molecular genetic testing is required to confirm diagnosis of CDG. Treatment options include feeding therapy for growth or eating problems, including special formula for a baby, thickening liquid foods, or the use of a nasogastric (NG) tube or G-tube.
For a complete picture of Congenital Disorder of Glycosylation’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
